Reviewing Cytosorbents Corporation (CTSO) & Accuray (ARAY)

Accuray (NASDAQ: ARAY) and Cytosorbents Corporation (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Accuray and Cytosorbents Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accuray 0 3 3 0 2.50
Cytosorbents Corporation 0 0 5 0 3.00

Accuray presently has a consensus target price of $6.60, indicating a potential upside of 41.94%. Cytosorbents Corporation has a consensus target price of $10.45, indicating a potential upside of 67.20%. Given Cytosorbents Corporation’s stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents Corporation is more favorable than Accuray.

Risk and Volatility

Accuray has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Cytosorbents Corporation has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500.


This table compares Accuray and Cytosorbents Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accuray -7.49% -55.18% -6.33%
Cytosorbents Corporation -67.83% -458.08% -67.14%

Earnings & Valuation

This table compares Accuray and Cytosorbents Corporation’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Accuray $383.41 million 1.02 -$29.57 million ($0.34) -13.68
Cytosorbents Corporation $9.53 million 18.82 -$11.93 million ($0.32) -19.53

Cytosorbents Corporation has higher revenue, but lower earnings than Accuray. Cytosorbents Corporation is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

74.9% of Accuray shares are held by institutional investors. Comparatively, 6.6% of Cytosorbents Corporation shares are held by institutional investors. 3.9% of Accuray shares are held by company insiders. Comparatively, 5.6% of Cytosorbents Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Cytosorbents Corporation beats Accuray on 7 of the 13 factors compared between the two stocks.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

About Cytosorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply